Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159455975> ?p ?o ?g. }
- W3159455975 endingPage "1298" @default.
- W3159455975 startingPage "1289" @default.
- W3159455975 abstract "The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults.Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in healthy Chinese adults aged 18 to 59 years. The participants in the phase 1 trial were randomized to receive two doses, one each on Days 0 and 14, of either KCONVAC (5 or 10 μg/dose) or placebo. The participants in the phase 2 trial were randomized to receive either KCONVAC (at 5 or 10 μg/dose) or placebo on Days 0 and 14 (0/14 regimen) or Days 0 and 28 (0/28 regimen). In the phase 1 trial, the primary safety endpoint was the proportion of participants experiencing adverse reactions/events within 28 days following the administration of each dose. In the phase 2 trial, the primary immunogenicity endpoints were neutralization antibody seroconversion and titer and anti-receptor-binding domain immunoglobulin G seroconversion at 28 days after the second dose.In the phase 1 trial, 60 participants were enrolled and received at least one dose of 5-μg vaccine (n = 24), 10-μg vaccine (n = 24), or placebo (n = 12). In the phase 2 trial, 500 participants were enrolled and received at least one dose of 5-μg vaccine (n = 100 for 0/14 or 0/28 regimens), 10-μg vaccine (n = 100 for each regimen), or placebo (n = 50 for each regimen). In the phase 1 trial, 13 (54%), 11 (46%), and seven (7/12) participants reported at least one adverse event (AE) after receiving 5-, 10-μg vaccine, or placebo, respectively. In the phase 2 trial, 16 (16%), 19 (19%), and nine (18%) 0/14-regimen participants reported at least one AE after receiving 5-, 10-μg vaccine, or placebo, respectively. Similar AE incidences were observed in the three 0/28-regimen treatment groups. No AEs with an intensity of grade 3+ were reported, expect for one vaccine-unrelated serious AE (foot fracture) reported in the phase 1 trial. KCONVAC induced significant antibody responses; 0/28 regimen showed a higher immune responses than that did 0/14 regimen after receiving two vaccine doses.Both doses of KCONVAC are well tolerated and able to induce robust immune responses in healthy adults. These results support testing 5-μg vaccine in the 0/28 regimen in an upcoming phase 3 efficacy trial.http://www.chictr.org.cn/index.aspx (No. ChiCTR2000038804, http://www.chictr.org.cn/showproj.aspx?proj=62350; No. ChiCTR2000039462, http://www.chictr.org.cn/showproj.aspx?proj=63353)." @default.
- W3159455975 created "2021-05-10" @default.
- W3159455975 creator A5018989202 @default.
- W3159455975 creator A5025392823 @default.
- W3159455975 creator A5027307547 @default.
- W3159455975 creator A5028939852 @default.
- W3159455975 creator A5036726873 @default.
- W3159455975 creator A5038282242 @default.
- W3159455975 creator A5041586518 @default.
- W3159455975 creator A5049507373 @default.
- W3159455975 creator A5053933911 @default.
- W3159455975 creator A5054369025 @default.
- W3159455975 creator A5063481153 @default.
- W3159455975 creator A5066716873 @default.
- W3159455975 creator A5066855201 @default.
- W3159455975 creator A5072289684 @default.
- W3159455975 creator A5076011780 @default.
- W3159455975 creator A5077645027 @default.
- W3159455975 creator A5082267036 @default.
- W3159455975 creator A5082485801 @default.
- W3159455975 date "2021-04-28" @default.
- W3159455975 modified "2023-10-03" @default.
- W3159455975 title "Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials" @default.
- W3159455975 cites W2022077288 @default.
- W3159455975 cites W2109820685 @default.
- W3159455975 cites W2153319819 @default.
- W3159455975 cites W2169656611 @default.
- W3159455975 cites W3001897055 @default.
- W3159455975 cites W3012650581 @default.
- W3159455975 cites W3027138240 @default.
- W3159455975 cites W3042383115 @default.
- W3159455975 cites W3042833857 @default.
- W3159455975 cites W3043722389 @default.
- W3159455975 cites W3048446898 @default.
- W3159455975 cites W3048620154 @default.
- W3159455975 cites W3083750089 @default.
- W3159455975 cites W3090717270 @default.
- W3159455975 cites W3102328262 @default.
- W3159455975 cites W3111255098 @default.
- W3159455975 cites W4225711802 @default.
- W3159455975 doi "https://doi.org/10.1097/cm9.0000000000001573" @default.
- W3159455975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8183795" @default.
- W3159455975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33928916" @default.
- W3159455975 hasPublicationYear "2021" @default.
- W3159455975 type Work @default.
- W3159455975 sameAs 3159455975 @default.
- W3159455975 citedByCount "46" @default.
- W3159455975 countsByYear W31594559752021 @default.
- W3159455975 countsByYear W31594559752022 @default.
- W3159455975 countsByYear W31594559752023 @default.
- W3159455975 crossrefType "journal-article" @default.
- W3159455975 hasAuthorship W3159455975A5018989202 @default.
- W3159455975 hasAuthorship W3159455975A5025392823 @default.
- W3159455975 hasAuthorship W3159455975A5027307547 @default.
- W3159455975 hasAuthorship W3159455975A5028939852 @default.
- W3159455975 hasAuthorship W3159455975A5036726873 @default.
- W3159455975 hasAuthorship W3159455975A5038282242 @default.
- W3159455975 hasAuthorship W3159455975A5041586518 @default.
- W3159455975 hasAuthorship W3159455975A5049507373 @default.
- W3159455975 hasAuthorship W3159455975A5053933911 @default.
- W3159455975 hasAuthorship W3159455975A5054369025 @default.
- W3159455975 hasAuthorship W3159455975A5063481153 @default.
- W3159455975 hasAuthorship W3159455975A5066716873 @default.
- W3159455975 hasAuthorship W3159455975A5066855201 @default.
- W3159455975 hasAuthorship W3159455975A5072289684 @default.
- W3159455975 hasAuthorship W3159455975A5076011780 @default.
- W3159455975 hasAuthorship W3159455975A5077645027 @default.
- W3159455975 hasAuthorship W3159455975A5082267036 @default.
- W3159455975 hasAuthorship W3159455975A5082485801 @default.
- W3159455975 hasBestOaLocation W31594559751 @default.
- W3159455975 hasConcept C126322002 @default.
- W3159455975 hasConcept C142724271 @default.
- W3159455975 hasConcept C159654299 @default.
- W3159455975 hasConcept C168563851 @default.
- W3159455975 hasConcept C197934379 @default.
- W3159455975 hasConcept C203014093 @default.
- W3159455975 hasConcept C203092338 @default.
- W3159455975 hasConcept C204787440 @default.
- W3159455975 hasConcept C27081682 @default.
- W3159455975 hasConcept C2777451964 @default.
- W3159455975 hasConcept C2780868878 @default.
- W3159455975 hasConcept C2781413609 @default.
- W3159455975 hasConcept C535046627 @default.
- W3159455975 hasConcept C71924100 @default.
- W3159455975 hasConceptScore W3159455975C126322002 @default.
- W3159455975 hasConceptScore W3159455975C142724271 @default.
- W3159455975 hasConceptScore W3159455975C159654299 @default.
- W3159455975 hasConceptScore W3159455975C168563851 @default.
- W3159455975 hasConceptScore W3159455975C197934379 @default.
- W3159455975 hasConceptScore W3159455975C203014093 @default.
- W3159455975 hasConceptScore W3159455975C203092338 @default.
- W3159455975 hasConceptScore W3159455975C204787440 @default.
- W3159455975 hasConceptScore W3159455975C27081682 @default.
- W3159455975 hasConceptScore W3159455975C2777451964 @default.
- W3159455975 hasConceptScore W3159455975C2780868878 @default.
- W3159455975 hasConceptScore W3159455975C2781413609 @default.
- W3159455975 hasConceptScore W3159455975C535046627 @default.
- W3159455975 hasConceptScore W3159455975C71924100 @default.